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Introduction 
 
Endometrial carcinoma (ECa) remains the most 
common gynecologic malignancy in the United 
States [1]. At presentation, over 85% of cases 
are stage I or II, and most patients with early-
stage disease can be cured with surgical resec-
tion or radiotherapy or a combination of the two 
[2]. Hormonal therapy with progestins and/or 
chemotherapy utilizing cisplatin, doxorubicin, 
and paclitaxel thus far have been regimens with 
activity in advanced or recurrent ECa [3, 4]. 
However, the response rates (RR) to these sys-
temic therapies have been consistently low. 
Progestins elicit a satisfactory response (usually 
in approximately 25 to 30%) in patients with 
high levels of hormonal receptor content. Treat-
ment with cisplatin and doxorubicin produces a 
RR of 42% with a median survival of nine 
months, whereas the addition of paclitaxel 
slightly increases the RR to 57% with an overall 
survival of approximately 12 months [4]. The 
lack of effective treatment, together with the 
considerable toxicities, underscores the need 
for novel therapeutic strategies, particularly 
targeted therapy with or without conventional 
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Abstract: The mammalian target of rapamycin (mTOR) assembles into two distinct complexes: mTOR complex 1 
(mTORC1) is predominantly cytoplasmic and highly responsive to rapamycin, whereas mTOR complex 2 (mTORC2) is 
both cytoplasmic and nuclear, and relatively resistant to rapamycin. mTORC1 and mTORC2 phosphorylatively regulate 
their respective downstream effectors p70S6K/4EBP1, and Akt. The resulting activated mTOR pathways stimulate 
protein synthesis, cellular proliferation, and cell survival. Moreover, phospholipase D (PLD) and its product, phos-
phatidic acid (PA) have been implicated as one of the upstream activators of mTOR signaling. In this study, we investi-
gated the activation status as well as the subcellular distribution of mTOR, and its upstream regulators and down-
stream effectors in endometrial carcinomas (ECa) and non-neoplastic endometrial control tissue. Our data show that 
the mTORC2 activity is selectively elevated in endometrial cancers as evidenced by a predominant nuclear localiza-
tion of the activated form of mTOR (p-mTOR at Ser2448) in malignant epithelium, accompanied by overexpression of 
nuclear p-Akt (Ser473), as well as overexpression of vascular endothelial growth factor (VEGF)-A isoform, the latter a 
resultant of target gene activation by mTORC2 signaling via hypoxia-inducible factor (HIF)-2alpha. In addition, expres-
sion of PLD1, one of the two major isoforms of PLD in human, is increased in tumor epithelium. In summary, we dem-
onstrate that the PLD1/PA-mTORC2 signal pathway is overactivated in endometrial carcinomas. This suggests that 
the rapamycin-insensitive mTORC2 pathway plays a major role in endometrial tumorigenesis and that therapies de-
signed to target the phospholipase D pathway and components of the mTORC2 pathway should be efficacious 
against ECa.  
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chemotherapy for advanced or recurrent ECa.  
 
mTOR is a serine/threonine kinase that is an 
essential regulator of cell growth, cell cycle pro-
gression and angiogenesis [5]. Currently, syn-
thetic mTOR inhibitors are being evaluated in 
clinical trials for treatment of patients with ad-
vanced or recurrent ECa [3]. In mammalian 
cells, mTOR assembles into two structurally and 
functionally distinct protein complexes, mTOR 
complex 1 (mTORC1) and mTOR complex 2 
(mTORC2). mTORC1 contains mTOR, raptor, and 
mLST8.  The assembly of mTORC1 predomi-
nantly occurs in the cytoplasm. The best charac-
terized downstream effector and target of 
mTORC1 are p70S6K and 4EBP1 (eukaryotic 
initiation factor 4E binding protein 1), respec-
tively [6, 7], both regulators of protein transla-
tion. In contrast, mTORC2, comprised of mTOR, 
rictor, mLST8 and mSin1, is abundant in both 
cytoplasmic and nuclear compartments. Upon 
growth factor stimulation, Akt is recruited to the 
plasma membrane and activated through phos-
phorylation at Thr308 by PDK1 and Ser473 by 
mTORC2 [5]. Activated Akt could subsequently 
phosphorylate and inactivate tuberin, causing 
increased mTORC1 activity [8]. VEGF expression 
is important for the neoangiogenesis, growth 
and metastasis of endometrial carcinoma, and 
it is regulated, at least in part, through the 
mTOR-dependent pathway [9, 10]. 
 
Recently, phospholipase D (PLD) and its me-
tabolites phosphatidic acid (PA) have been im-
plicated as one of the upstream regulators of 
the mTOR signaling. PLD in response to mito-
genic signals catalyzes the hydrolysis of phos-
phatidylcholine to choline and PA [11]. Binding 
of PA facilitates the association of mTOR with 
raptor to form mTORC1 and that of mTOR with 
rictor to form mTORC2. The effect of PA is com-
petitive with rapamycin, a natural mTOR inhibi-
tor, and as a consequence, elevated PLD activ-
ity may confer resistance to rapamycin [12]. 
Overexpression of PLD has been observed in a 
variety of human cancers, including breast can-
cer, gastric cancer, and renal cell carcinoma 
[13]. To date, only a few investigations have 
been performed to assess the expression of 
mTOR signaling cascade in invasive endometrial 
carcinomas [14, 15]. Furthermore, the subcellu-
lar localization of the activated form of mTOR in 
these tumors has not been characterized. De-
termining the cytoplasmic and nuclear distribu-
tion of activated mTOR and thus understanding 
the relative extent of involvement of mTORC1 
and mTORC2 in endometrial carcinoma is im-
portant, as mTORC1 is highly sensitive to rapa-
mycin, whereas mTORC2 is relatively resistant 
to the effects of rapamycin [16]. Thus, the aim 
of the present study was to characterize the 
mTOR activation status via a morphoproteomic 
examination of the expression and subcellular 
distribution of mTOR and its upstream regula-
tors and downstream effectors in endometrial 
carcinoma (ECa), as well as in proliferative-
phase endometrium (PE), and secretory-phase 
endometrium (SE) [17,18].  
 
Materials and methods 
 
Specimens 
 
A total of 83 cases including 33 cases of ECa, 
25 cases of PE, and 25 cases of SE were re-
trieved from the surgical pathology files at the 
Department of Pathology, the Lyndon B Johnson 
General Hospital and the Memorial Hermann 
Hospital at Texas Medical Center. Among the 33 
cases of ECa, 11 (33%) are International Fed-
eration of Gynecology and Obstetrics (FIGO) 
grade 1, 19 (58%) are FIGO grade 2, 3 (9%) are 
FIGO grade 3, and one patient (3%) had been 
treated with medroxyprogesterone prior to hys-
terectomy.  
        
The tissues were made anonymous and dissoci-
ated from any clinical information. The hema-
toxylin and eosin (H&E) stained slides were re-
viewed and the diagnoses were confirmed by 
two pathologists. Corresponding formalin-fixed, 
paraffin-embedded tissue blocks were obtained 
and tissue microarrays were constructed with a 
tissue arrayer (Beecher Instruments, Sun Prai-
rie, WI) by selecting a 1-mm tissue core from 
each case. H&E staining of the microarray sec-
tions demonstrated histologically representative 
areas of the tumors.  
 
Immunohistochemical staining 
 
Antibodies utilized in this study included: phos-
phorylated (p)-mTOR at Serine 2448, p-Akt at 
Serine 473( Cell Signaling Technology, Inc, Bev-
erly, MA); vascular endothelial growth factor 
(VEGF)-A isoform (DakoCytomation, Carpentaria, 
CA); and phospholipase D 1 (PLD1), and phos-
pholipase D 2 (PLD2) (Santa Cruz Biotechnol-
ogy, Inc, Santa Cruz, CA). After deparaffinization 
in xylene and rehydration in ethanol, heat-
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induced epitope retrieval was performed on 
tissue microarray sections. The tissue was 
treated with 3% H2O2 and washed with tris-
buffered saline (TBS)/Tween-20. A few drops of 
diluted blocking serum were added on the tis-
sue and incubated at room temperature. The 
sections were then incubated with the primary 
antibodies. (Those incubated with anti-
phosphospecific probes were incubated over-
night at 4 degrees centigrade, per the vendors 
recommended procedure).  The rest of the 
staining procedure was performed on a DAKO 
autostainer (Carpinteria, CA, United States) pro-
grammed to incubate each slide with diluted 
biotinylated secondary antibodies, rinse slides, 
and incubate with DAB solution (3, 3’-
diaminobenzidine chromogen solution). The 
slides were then counterstained with hematoxy-
lin, dehydrated, and cover-slipped. Positive and 
negative controls were run in parallel with the 
samples.  
 
Tissue microarray scoring 
 
Chromogenic signals were evaluated by bright-
field microscopy and semi-quantified with re-
gard to percentage of cells stained (0-100%) 
and the staining intensity (0: non-staining, 1+: 
weak staining, 2 +: moderate staining, and 3 +: 
strong staining). In addition, the cellular com-
partmentalization of each signal was indicated 
as plasmalemmal (membranous), cytoplasmic, 
or nuclear. Cases in which no core was available 
were excluded from analysis.     
 
Statistical analysis 
 
Pearson's chi-square test was used to deter-
mine statistical significance of differences in 
frequency of strong positive (staining intensity 2
-3+) expression of analytes between ECa and 
benign endometrial tissues (PE and SE). Med-
Calc (Mariakerke, Belgium) software was used 
for statistical analysis and P values less than 
0.05 were considered statistically significant.  
 
Results  
 
Expression and subcellular localization of p-
mTOR (Ser2448) 
 
Analysis of different subcellular fractions of the 
endometrial epithelial cells revealed that plas-
malemmal/cytoplasmic p-mTOR (Ser2448) im-
munopositivity was the main staining pattern in 
the non-neoplastic cells (Figure 1 and 2). 19 of 
24 PE (79%) and 11 of 23 SE (46%) showed 
moderate to strong (2-3+) plasmalemmal /
cytoplasmic expression of p-mTOR (Ser2448), 
whereas only one third of PE and SE had weak 
(1+) nuclear p-mTOR (Ser2448) staining. In con-
trast, nuclear staining of p-mTOR was the pre-
dominant pattern in ECa and was detected in all 
32 cases examined. Moderate to strong (2-3+) 
nuclear p-mTOR (Ser2448) staining was de-
tected in 9 of 32 (30%) of ECa cases, whereas 
none of the 47 non-cancerous cases (24 PE and 
23 SE) showed moderate to strong (2-3+) nu-
clear p-mTOR expression (Figure 1 and 2, Table 
1). Statistical analysis revealed that moderate 
to strong (2-3+) nuclear p-mTOR (Ser2448) ex-
pression was more frequently observed in ECa 
compared with benign endometrial tissues (PE 
and SE) (p < .001, see Table 1). These results 
suggest a selective overactivation of mTORC2 in 
endometrial carcinomas.  
 
Expression and subcellular localization of p-Akt 
(Ser473), a readout of mTORC2 activity 
 
The expression of p-Akt at Ser473 is seen in 
both cytoplasmic and nuclear compartments in 
all groups. 20 of 33 ECa (61%) showed moder-
ate to strong (2-3+) nuclear p-Akt (Ser473) im-
munopositivity; however, only 7 of 27 PE (26%) 
and none of the 22 SE cases (0%) had moder-
ate to strong (2-3+) nuclear p-Akt (Ser473) 
staining (Figure 3). Moderate to strong nuclear 
p-Akt (Ser473) expression was more frequently 
observed in ECa compared with benign endo-
metrial tissues (PE and SE) (p < .001, see Table 
1). The cytoplasmic expression of p-Akt 
(Ser473) does not show statistically significant 
difference between the cancerous (ECa) and 
non-cancerous groups (PE and SE) (p = 0.08, 
see Table 1). These results correlate with the 
predominant nuclear staining of p-mTOR (Ser 
2448) in ECa vis-a-vis benign endometrial epi-
thelium.  
 
Expression of VEGF-A, the product of a target 
gene of mTORC2 signaling via hypoxia-inducible 
factor-2alpha [19, 20]  
 
The plasmalemmal and cytoplasmic expression 
of VEGF-A was weak (1+) in most cases of PE 
and SE, with less than 20% showing moderate 
to strong (2-3+) VEGF-A staining in both groups, 
whereas moderate and strong VEGF-A expres-
sion was detected in a substantially higher pro-
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portion of ECa cases (55%, 18/32) (Figure 3 
and Table 1). Moderate to strong (2-3+) VEGF-A 
expression was more frequently observed in 
Figure 1. Representative hematoxylin-eosin (H&E) 
depictions of endometrial carcinoma (ECa), prolifera-
tive-phase endometrium (PE), and secretory-phase 
endometrium (SE), respectively. Original magnifica-
tion x 400.  
Figure 2. Expression of p-mTOR (Ser2448) in endo-
metrial carcinoma (ECa), proliferative-phase endo-
metrium (PE), and secretory-phase endometrium 
(SE). Phosphospecific antibodies against p-mTOR at 
serine 2448 show brown chromogenic signals in the 
plasmalemmal/cytoplasmic compartments of prolif-
erative and secretory endometrium, and the signals 
are largely confined to the nucleus of tumor cells, 
the latter most consistent with mTORC2. Original 
magnification x 400.  
Phospholipase D1-mTORC2 and endometrial carcinoma 
 
 
17                                                                                                              Int J Clin Exp Pathol 2011;4(1):13-21 
ECa than in benign endometrial tissues (PE and 
SE) (p = 0.001, see Table 1). 
 
Expression of PLD1 and PLD2, upstream facili-
tators of mTORC1/ mTORC2 signaling 
 
The expression of PLD1 is seen in both cyto-
plasm and nucleoli in all groups. Moderate (2+) 
cytoplasmic PLD1 expression is observed in 
37% ECa but none in PE or SE; in addition, 71% 
PE and 71% SE show a complete lack of PLD1 
expression (Figure 4). Moderate to strong (2-3+) 
PLD1 expression was more frequently observed 
in ECa compared with benign endometrial tis-
sues (PE and SE) (p < 0.001, see Table 1). 
PLD2 shows a moderate to strong (2-3+) cyto-
plasmic signal in all groups (figure not shown). 
No marked differences in the PLD2 expression 
level are noted among the three groups (p = 
0.21, see Table 1).  
 
Discussion 
 
Morphoproteomics [18] attempts to define the 
biology of tumors by: utilizing phosphospecific 
immunohistochemical probes directed against 
putative sites of activation of signal transduc-
tion molecules and characterizing their subcel-
lular compartmentalization (nuclear, cytoplas-
mic and plasmalemmal); assessing the correla-
tive expression of effectors downstream of an 
activated pathway and of protein analytes asso-
ciated with its enhancement; and comparing the 
signal intensity of such analytes in tumor cells 
versus those in their non-neoplastic counterpart 
as an indication of overexpression.  Applied to 
this study, we have shown the overexpression of 
the following protein analytes in endometrial 
carcinoma:  nuclear p-mTOR (Ser 2448) and 
nuclear p-Akt (Ser 473), indicative of mTORC2 
pathway expression [21, 5]; VEGF-A, consistent 
with downstream signaling by the mTORC2 
pathway via hypoxia-inducible factor-2alpha [19, 
20,22];  and phospholipase D1, whose product, 
phosphatidic acid facilitates mTOR complex 
formation and which appears to be involved in 
the activation of mTORC2 [12, 23]. A computer-
assisted search of the National Library of Medi-
cine's MEDLINE database provides clinical cor-
relates for our observations and conclusion that 
Table 1. Morphoproteomic Detection and Subcellular Compartmentalization of p-mTOR (Ser 2448), p-Akt 
(Ser 473), VEGF-A and PLD Analytes in Endometrial Carcinoma versus Proliferative and Secretory Endo-
metrial Glands 
Protein 
analytes 
Staining 
intensity 
ECa PE SE Frequency of 2-3+ 
expression in ECa vs. 
PE & SE: p value# 
Nuclear 
p-mTOR 
(Ser2448) 
1+ 23/32 (70%) 8/24 (33%) 7/23 (32%)   
     < .001 2-3+ 9/32 (30%) 0/24 (0%) 0/23 (0%) 
Cytoplasmic p-
AKT 
(Ser473) 
1+ 27/33 (82%) 25/27 (93%) 22/22 (100%)   
       .084 2-3+ 6/33 (18%) 2/27 (7%) 0/22 (0%) 
Nuclear 
p-AKT (Ser473) 
1+ 13/33 (39%) 20/27 (74%) 22/22 (100%)   
    < .001 2-3+ 20/33 (61%) 7/27 (26%) 0/22 (0%) 
VEGF-A+ 1+ 13/32 (41%) 19/23 (83%) 14/22 (64%)   
       .001 2-3+ 18/32 (55%) 4/23 (17%) 4/22 (19%) 
Cytoplasmic 
PLD1 
1+ 13/33 (39%) 7/24 (29%) 6/21 (29%)   
    < .001 2+  12/33 (37%) 0/24 (0%) 0/21 (0%) 
Cytoplasmic 
PLD2 
1+ 0/33 (0%) 0/24 (0%) 0/21 (0%)   
       .21 2-3+ 33/33 (100%) 24/24 (100%) 21/21 (100%) 
1+: weak; 2+: moderate; 3+: strong. +: Both plasmalemmal and cytoplasmic staining.  #: Significance of differences in frequency of 
positive strong (2-3+) expression in ECa and benign endometrial tissues (PE and SE) is determined by Pearson's chi-square test 
(degrees of freedom: 1). 
  
Abbreviations: ECa (endometrial carcinoma); PE (proliferative endometrial glands); SE (secretory endometrial glands); mTOR 
(mammalian target of rapamycin); VEGF (vascular endothelial growth factor)-A; PLD (phospholipase D) 
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Figure 3. Expression of downstream effectors of mTORC2 pathway in endometrial carcinoma (ECa), proliferative-
phase endometrium (PE), and secretory-phase endometrium (SE). Phosphospecific antibodies against p-Akt at serine 
473 show chromogenic signals in the cytoplasm and nucleus of epithelial cells in all three groups (left column) with 
relatively overexpression of nuclear p-Akt (Ser473) in the ECa. Antibodies recognizing VEGF-A show chromogenic sig-
nals in the plasmalemmal/cytoplasmic fractions of both non-neoplastic and neoplastic epithelial cells (right column) 
with relative overexpression in the ECa. Original magnification x 400.      
Phospholipase D1-mTORC2 and endometrial carcinoma 
 
 
19                                                                                                              Int J Clin Exp Pathol 2011;4(1):13-21 
the mTORC2 pathway predominates and is fa-
cilitated by the phospholipase D1 pathway in 
endometrial carcinoma. Moreover, such corre-
lates provide insight into new therapeutic strate-
gies that target the phospholipase D-mTORC2 
pathway in the treatment of patients with endo-
metrial carcinoma.   
 
We believe that our findings of the preferential 
mTORC2 pathway activation in endometrial car-
cinoma in contrast to the preponderant 
mTORC1 pathway activation in proliferative and 
secretory endometrium are in accord with the 
observation of McCampbell and co-workers, 
who demonstrated loss of inhibitory insulin re-
ceptor substrate (IRS)-1 phosphorylation in the 
majority of endometrial carcinoma as compared 
with normal proliferative endometrium [24, 25]. 
Such concordance is strengthened and ex-
plained, at least in part  by the  report of Tzatsos 
who observed that binding of IRS with raptor of 
mTORC1 is necessary to effect inhibitory phos-
phorylation of IRS-1 at serine 636/639 [26].   
  
Additionally, the expression of IRS-1 and/or IRS-
2 in the majority of the endometrial carcinomas 
reported by McCampbell et al [24] is also con-
sistent with our findings of mTORC2 in ECa, as 
well as the established literature. This is based 
on several findings. First, signaling by insulin-
like growth factor (IGF)-1 receptor leads to 
translocation of IRS-1 and IRS-2 to the nucleus 
[27], the latter, IRS-2 has been shown to form 
complexes with rictor/mTORC2 [28]. Second, 
IGF stimulates downstream effectors in the 
mTORC2 pathway, namely HIF-2alpha and VEGF
-A [20, 29], the latter is shown to be overex-
pressed in our study. Moreover, the overexpres-
sion of phospholipase D1 in our series of endo-
metrial carcinomas could explain the seemingly 
paradoxical finding reported by McCampbell et 
al., of the frequent expression of phospho-S6 
ribosomal protein (S235), a down-
stream effector of p70S6K signaling in the ab-
sence of the expected p70S6K-induced phos-
phorylative inactivation of IRS-1 in endometrial 
carcinomas. Phosphatidic acid, the product of 
phospholipase D activity can directly phosphory-
late p70S6K on threonine 389 [30] and 
thereby, account for activation of S6 ribosomal 
protein in the absence of mTORC1 signaling. 
Finally, a phase 2 clinical trial using everolimus, 
a rapalog with both mTORC1 and mTORC2 in-
hibitory properties produced a clinical benefit 
response in 21% (6 out of 28 patients) of pa-
tients with recurrent endometrial carcinoma at 
20 weeks of therapy [31].  
 
Most importantly, the constellation of findings 
Figure 4. Expression of PLD1 in endometrial carci-
noma (ECa), proliferative-phase endometrium (PE), 
and secretory-phase endometrium (SE). Isoform-
specific antibodies against PLD1 show chromogenic 
signals in both cytoplasm and nucleoli in both non-
neoplastic and neoplastic epithelial cells but with 
relative cytoplasmic overexpression in the ECa. Origi-
nal magnification x 400.   
Phospholipase D1-mTORC2 and endometrial carcinoma 
 
 
20                                                                                                              Int J Clin Exp Pathol 2011;4(1):13-21 
from our morphoproteomic analysis of this se-
ries of patients with endometrial carcinoma, 
when viewed in the context of the scien-
tific literature raises new therapeutic options. 
Metformin is one such consideration for the 
following reasons: (1) metformin is an AMP de-
pendent kinase (AMPK) agonist and has been 
shown to phosphorylatively inactivate IRS-1 at 
serine 789, downregulate Akt phosphorylated at 
serine 473, mTOR phosphorylated at serine 
2448, IGF-1R and IRS-1 levels [32]; (2) met-
formin reduces IGF-1 levels [33] and  IGF-1-
induced HIF-1alpha expression[34]; (3) met-
formin directly inhibits the phosphorylation of 
p70S6K, independent of the AMPK pathway 
[35]; and (4) metformin has been shown to 
downregulate the levels of lysophosphatidylcho-
line and phosphatidylcholine the substrates for 
phospholipase D [36]. In a preclinical study on 
endometrial cancer cell lines, metformin has 
been shown to inhibit cell proliferation, medi-
ated at least in part through the inhibition of the 
mTOR pathway [37].   
  
In summary, morphoproteomic analysis re-
veals the overexpression of nuclear p-mTOR 
(Ser 2448) and p-Akt (Ser 473) and of VEGF-A 
isoform and phospholipase D1 in endometrial 
carcinoma vis-a-vis benign proliferative and sec-
retory endometrium. This constellation of find-
ings supports the presence of the mTORC2 
pathway in the biology of endometrial cancer 
and suggests new possible therapeutic ap-
proaches to target the phospholipase D1-
mTORC2 pathway.   
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